Conducting clinical trials on tuberculosis in resource-poor countries: Imposed science or equally-shared efforts?

International Journal of Tuberculosis and Lung Disease

Volumn 9, Issue 9, 2005, Pages 943-

  Lienhardt, Christian ^a,b   Cook, Sharlette V ^b  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (Senegal)

^b Clinical Trial Division   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

CLINICAL TRIAL; COMORBIDITY; DEVELOPING COUNTRY; EDITORIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; RESOURCE ALLOCATION; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANIMALS; CLINICAL TRIALS; DEVELOPING COUNTRIES; ETHICS, RESEARCH; TUBERCULOSIS;

EID: 27644531877     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (5)

1. Nundy S, Chir M, Gulhati M. A new colonialism? Conducting clinical trials in India. N Engl J Med 2005; 352: 1633-1636.
2. Richards T. Conduct of clinical trials in poor countries must improve. BMJ 2005; 330: 1466.
3. Mwinga A, Fourie P B. Prospects for new anti-tuberculosis treatment in Africa. Trop Med Int Health 2004; 9: 827-832.
4. Brindle R, Odhiambo J, Mitchison D A. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilizing activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm Med 2001; 1: 2-9.
5. Jindani A, Nunn A J, Enarson D A. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364: 1244-1251.